Zytiga the new drug for prostate cancer has now reached blockbuster status surpassing the billion dollar annual sales rate. Johnson & Johnson third quarter sales of Zytiga have now broken through the $ 250 M barrier reaching $ 265 M for this last quarter of a year.
These are remarkable sales figures that have been reached in a short space of time since the drug was only FDA approved in April last year. The rapid uptake of Zytiga reflects the medical oncologists confidence in its efficacy and safety profile. The drug is very well tolerated and the responses in many cases are phenomenal.
Over half the sales were accounted for from the United States alone and European sales are set to increase yet further. Zytiga is now on the national formulary in many European countries and has been approved for prescription use on the NHS in the UK which paves the way for more widespread usage.
No comments:
Post a Comment